Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 127


Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.

Lemma SA, Pasanen AK, Haapasaari KM, Sippola A, Sormunen R, Soini Y, Jantunen E, Koivunen P, Salokorpi N, Bloigu R, Turpeenniemi-Hujanen T, Kuittinen O.

Eur J Haematol. 2015 Jul 7. doi: 10.1111/ejh.12626. [Epub ahead of print]


High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index.

Kuusisto ME, Haapasaari KM, Turpeenniemi-Hujanen T, Jantunen E, Soini Y, Peroja P, Bloigu R, Karihtala P, Kuittinen O.

J Clin Pathol. 2015 Jul;68(7):552-6. doi: 10.1136/jclinpath-2014-202771. Epub 2015 May 2.


Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.

Harjama L, Kuitunen H, Turpeenniemi-Hujanen T, Haapasaari KM, Leppä S, Mannisto S, Karjalainen-Lindsberg ML, Lehtinen T, Eray M, Vornanen M, Haapasalo H, Soini Y, Jantunen E, Nousiainen T, Vasala K, Kuittinen O.

Acta Oncol. 2015 Jun;54(6):939-43. doi: 10.3109/0284186X.2014.990110. Epub 2015 Mar 11.


Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma.

Kuusisto ME, Haapasaari KM, Remes AM, Bloigu R, Karihtala P, Turpeenniemi-Hujanen T, Kuittinen O.

Ann Hematol. 2015 Jul;94(7):1167-74. doi: 10.1007/s00277-015-2334-y. Epub 2015 Feb 21.


Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas.

Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, Kuittinen O, Auvinen P, Marin K, Koivunen P, Sormunen R, Soini Y, Karihtala P.

Histopathology. 2014 Sep;65(3):319-27. doi: 10.1111/his.12389. Epub 2014 Apr 3.


Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.

Honkavuori-Toivola M, Santala M, Soini Y, Turpeenniemi-Hujanen T, Talvensaari-Mattila A.

Dis Markers. 2013;35(4):261-6.


[Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma].

Kuittinen O, Siniluoto T, Isokangas M, Turpeenniemi-Hujanen T, Peltonen J, Alahuhta S, Sonkajärvi E.

Duodecim. 2013;129(15):1563-70. Review. Finnish.


Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma.

Lilja L, Haapasaari KM, Bloigu R, Salonen T, Ristimäki A, Turpeenniemi-Hujanen T, Kuittinen O.

Histopathology. 2013 Sep;63(3):438-9. doi: 10.1111/his.12162. Epub 2013 Jun 26. No abstract available.


Cell cycle regulation score predicts relapse-free survival in non-germinal centre diffuse large B-cell lymphoma patients treated by means of immunochemotherapy.

Pasanen AK, Haapasaari KM, Peltonen J, Soini Y, Jantunen E, Bloigu R, Turpeenniemi-Hujanen T, Kuittinen O.

Eur J Haematol. 2013 Jul;91(1):29-36. doi: 10.1111/ejh.12117. Epub 2013 May 3.


Circulating matrix metalloproteinase MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancy failure.

Nissi R, Talvensaari-Mattila A, Kotila V, Niinimäki M, Järvelä I, Turpeenniemi-Hujanen T.

Reprod Biol Endocrinol. 2013 Jan 15;11:2. doi: 10.1186/1477-7827-11-2.


2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H; PROSTY study group.

Lancet Oncol. 2013 Feb;14(2):117-24. doi: 10.1016/S1470-2045(12)70537-5. Epub 2013 Jan 4.


Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma.

Peroja P, Pasanen AK, Haapasaari KM, Jantunen E, Soini Y, Turpeenniemi-Hujanen T, Bloigu R, Lilja L, Kuittinen O, Karihtala P.

Exp Hematol Oncol. 2012 Mar 26;1(1):2. doi: 10.1186/2162-3619-1-2.


Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma.

Lemma S, Karihtala P, Haapasaari KM, Jantunen E, Soini Y, Bloigu R, Pasanen AK, Turpeenniemi-Hujanen T, Kuittinen O.

Histopathology. 2013 Jan;62(2):326-33. doi: 10.1111/his.12000. Epub 2012 Nov 27.


Snail promotes an invasive phenotype in lung carcinoma.

Merikallio H, Turpeenniemi-Hujanen T, Pääkkö P, Mäkitaro R, Riitta K, Salo S, Salo T, Harju T, Soini Y.

Respir Res. 2012 Nov 17;13:104. doi: 10.1186/1465-9921-13-104.


Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.

Kuvaja P, Hulkkonen S, Pasanen I, Soini Y, Lehtonen S, Talvensaari-Mattila A, Pääkkö P, Kaakinen M, Autio-Harmainen H, Hurskainen T, Lehenkari P, Turpeenniemi-Hujanen T.

Exp Cell Res. 2012 Jun 10;318(10):1094-103. doi: 10.1016/j.yexcr.2012.03.009. Epub 2012 Mar 23.


Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.

Honkavuori-Toivola M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T, Santala M.

Tumour Biol. 2012 Aug;33(4):935-41. doi: 10.1007/s13277-012-0321-7. Epub 2012 Jan 21.


Long-term prognosis of breast cancer detected by mammography screening or other methods.

Lehtimäki T, Lundin M, Linder N, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Isola J, Joensuu H, Lundin J.

Breast Cancer Res. 2011;13(6):R134. doi: 10.1186/bcr3080. Epub 2011 Dec 28.


Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas.

Pasanen AK, Kuitunen H, Haapasaari KM, Karihtala P, Kyllönen H, Soini Y, Turpeenniemi-Hujanen T, Kuittinen O.

Leuk Lymphoma. 2012 Apr;53(4):624-31. doi: 10.3109/10428194.2011.624226. Epub 2011 Dec 13.


Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.

Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H.

Breast Cancer Res. 2011 Sep 13;13(5):R87. doi: 10.1186/bcr2944.


Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.

Peltonen JK, Vähäkangas KH, Helppi HM, Bloigu R, Pääkkö P, Turpeenniemi-Hujanen T.

Head Neck Oncol. 2011 Apr 22;3:20. doi: 10.1186/1758-3284-3-20.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk